GIM
VRTX icon

Glenmede Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Glenmede Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.87M Buy
4,768
+96
+2% +$40.1K 0.01% 570
2025
Q2 		$2.08M Buy
+4,672
New +$2.15M 0.01% 564

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Glenmede Investment Management's VRTX Position: Q3 2025 in Review

Glenmede Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q3 2025, buying an estimated $40.1K and bringing the position to 4,768 shares worth $1.87M. The position accounts for 0.01% of the portfolio, ranked #570.

Glenmede Investment Management first reported a position in VRTX in Q2 2025 and has held it in 2 quarters since. The position peaked at $2.08M in Q2 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Glenmede Investment Management held 4,768 shares of Vertex Pharmaceuticals worth $1.87M as of Q3 2025.
  • Glenmede Investment Management bought 96 Vertex Pharmaceuticals shares in Q3 2025, an estimated $40.1K.
  • Vertex Pharmaceuticals made up 0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #570 holding.
  • Glenmede Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Vertex Pharmaceuticals position peaked at $2.08M in Q2 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.